Product Wiki · Recalls · EU Safety Gate (RAPEX)

Essaco — recall A12/01600/24

EU Safety Gate (RAPEX) · Lithuania · 2024-06-21 · Serious risk

Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
A12/01600/24
Date of alert
2024-06-21
Country / jurisdiction
Lithuania
Risk level
Serious risk
Risk type
Chemical
Product category
Jewellery
Product type
Bracelet
Barcode (EAN/GTIN)
2210131560542
Reported risk: Nikelio išsiskyrimo greitis per didelis (išmatuota vertė iki 0,19 µg/cm²/sav.). Nikelis yra stiprus sensibilizatorius ir gali sukelti alergines reakcijas, jei jo yra gaminiuose, kurie tiesiogiai ir ilgai liečiasi su oda. Produktas neatitinka REACH reglamento.
Action taken by the authority
Type of economic operator to whom the measure were ordered
Retailer
Category of measure
Withdrawal of the product from the market
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.

Product Name (original English): Essaco

Risk Description (original English): The rate of nickel release is too high (measured value up to 0.19 μg/cm²/week). Nickel is a strong sensitiser and can cause allergic reactions if present in articles that come into direct and prolonged contact with the skin.

Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/10013430

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.